Unless patients were further treated with more leronlimab or another drug outside of SOC, they should still be trial-worthy beyond 42 days.

The question would probably be how many, if not all, of the patients doctors can definitely report as to the outcomes of the endpoints. The 60 days means 2+ weeks more than doctors expected to follow-up with their patients. If docs are keeping tabs on all of their patients it may not be an issue but there is the possibility that a few could fall through the cracks and be reported as unknown status at 60 days.